Literature DB >> 20106348

The Will Rogers phenomenon: the effect of different diagnostic criteria.

Maria Pia Sormani1.   

Abstract

The 'Will Rogers phenomenon' is an apparent epidemiological paradox named after a remark made by the humorist Will Rogers about migration during the American economic depression of the 1930's: "When the Okies left Oklahoma and moved to California, they raised the average intelligence level in both states." In 1985, Alvan Feinstein proposed the name 'Will Rogers Phenomenon' to describe the 'stage migration' he observed in patients with cancer. Changes in the criteria for assigning patients to the various stages of a disease can produce spurious improvements in stage-specific prognosis, even though the outcome of individual patients has not changed. In oncology, new imaging tools allowed detection of cancer metastases before they became evident clinically. In consequence, more patients are classified into the more severe metastatic disease stage from the less severe single tumour stage. Such a 'stage migration' resulted in an improved survival of patients in both the less and the more severe disease stages. Multiple sclerosis is also subject to the Will Rogers phenomenon since the introduction of the imaging-assisted McDonald criteria. Given the sensitivity of magnetic resonance imaging for detecting disease activity, which is believed to be five to ten times greater than that of clinical assessment, the McDonald criteria are expected to allow earlier diagnosis, hence the 'stage migration' relative to the previous Poser diagnostic criteria. Because of the ethical problems associated with carrying out placebo-controlled trials in multiple sclerosis owing to the wider availability of therapeutic options, the use of historical controls groups remains an attractive option. However, the Will Rogers phenomenon, which is recognised as one of the most important biases limiting the use of historical controls groups in experimental treatment trials, compromises the interest of this approach. In this context, the use of different diagnostic criteria may generate spurious improvements in the medium-term prognosis of multiple sclerosis, which may be wrongly interpreted as treatment effects. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 20106348     DOI: 10.1016/S0022-510X(09)71300-0

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  18 in total

1.  Open surgical treatment for esophageal cancer: transhiatal vs. transthoracic, does it really matter?

Authors:  Uriel Clemente-Gutiérrez; Heriberto Medina-Franco; Oscar Santes; Jesús Morales-Maza; Alejandro Alfaro-Goldaracena; Martin J Heslin
Journal:  J Gastrointest Oncol       Date:  2019-08

2.  Minimal Increase in Survival Throughout the Years in Patients with Soft Tissue Sarcoma with Synchronous Metastases: Results of a Population-Based Study.

Authors:  Melissa Vos; Vincent K Y Ho; Astrid W Oosten; Cornelis Verhoef; Stefan Sleijfer
Journal:  Oncologist       Date:  2018-09-06

3.  Interval between neoadjuvant treatment and definitive surgery in locally advanced rectal cancer: impact on response and oncologic outcomes.

Authors:  Felipe A Calvo; Virginia Morillo; Marcos Santos; Javier Serrano; Marina Gomez-Espí; Marcos Rodriguez; Emilio Del Vale; Jose Luis Gracia-Sabrido; Carlos Ferrer; Claudio Sole
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-01       Impact factor: 4.553

4.  Bias in Hazard Ratios Arising From Misclassification According to Self-Reported Weight and Height in Observational Studies of Body Mass Index and Mortality.

Authors:  Katherine M Flegal; Brian K Kit; Barry I Graubard
Journal:  Am J Epidemiol       Date:  2018-01-01       Impact factor: 4.897

Review 5.  Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.

Authors:  Ralf Gold
Journal:  CNS Drugs       Date:  2011-01       Impact factor: 5.749

6.  Cancer incidence and staging among American Indians in Oklahoma.

Authors:  Janis E Campbell; Sydney A Martinez; Amanda E Janitz; Anne E Pate; Julie Erb-Alvarez; David F Wharton; David Gahn; Vicki L Tall; Cuyler Snider; Tom Anderson; Michael Peercy
Journal:  J Okla State Med Assoc       Date:  2014-03

7.  Axillary lymph node dissection in node-positive breast cancer: are ten nodes adequate and when is enough, enough?

Authors:  Laura H Rosenberger; Yi Ren; Samantha M Thomas; Rachel A Greenup; Oluwadamilola M Fayanju; E Shelley Hwang; Jennifer K Plichta
Journal:  Breast Cancer Res Treat       Date:  2019-11-18       Impact factor: 4.872

8.  FDG-PET/CT in high-risk primary breast cancer-a prospective study of stage migration and clinical impact.

Authors:  Marianne Vogsen; Jeanette Dupont Jensen; Ivar Yannick Christensen; Oke Gerke; Anne Marie Bak Jylling; Lisbet Brønsro Larsen; Poul-Erik Braad; Katrine Lydolph Søe; Camilla Bille; Marianne Ewertz; Malene Grubbe Hildebrandt
Journal:  Breast Cancer Res Treat       Date:  2020-09-12       Impact factor: 4.872

Review 9.  Diagnostic Criteria, Classification and Treatment Goals in Multiple Sclerosis: The Chronicles of Time and Space.

Authors:  Achilles Ntranos; Fred Lublin
Journal:  Curr Neurol Neurosci Rep       Date:  2016-10       Impact factor: 5.081

Review 10.  Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis.

Authors:  Eleonora Cocco; Maria Giovanna Marrosu
Journal:  Ther Clin Risk Manag       Date:  2015-05-08       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.